1 / 17

GCC Biosimilar Market Size, Share, Industry Analysis 2022-2027

The expanding geriatric population and the growing prevalence of chronic diseases, such as cancer, diabetes, rheumatoid arthritis, etc., are primarily driving the GCC biosimilar market. Additionally, several branded biologics are nearing their expiration dates, which in turn, is catalyzing the market growth. <br><br>Know more: https://www.syndicatedanalytics.com/gcc-biosimilar-market

peter55
Download Presentation

GCC Biosimilar Market Size, Share, Industry Analysis 2022-2027

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. GCC Biosimilar Market, Share, Size, Trends and Forecast 2022-2027 Copyright © 2015 International Market Analysis Research & Consulting (IMARC). All Rights Reserved https://www.syndicatedanalytics.com sales@syndicatedanalytics.com +1-213-316-7435

  2. About Syndicated Analytics Report Description Syndicated Analytics, a subsidiary of IMARC Group, offers consulting services and provides comprehensive market intelligence in the form of research reports, production cost reports and feasibility studies. Our team, consisting of experienced researchers and analysts from diverse industries, is deeply committed to the quality of the information and insights delivered to the clients, which range from small and medium enterprises to Fortune 1000 companies. These firms are able to achieve this by studying the qualitative and quantitative aspects of the market as well as staying up-to-date with the current and the evolving trends of the industry. Our set of syndicated as well as customized research reports and studies help clients in conducting an early-stage analysis to validate the availability of necessities such as raw materials, plant and machinery, and packaging requirements. These reports also assist stakeholders in understanding the market trends prevalent in the industry and gaining a better view of their competitive landscape, overcoming various industry-related challenges and formulating revenue-generating business strategies for entering the industry. Our Intelligence Overage: Our research reports provide deep insights on market intelligence at the global as well as the regional level, covering the ASEAN, BRICS, and GCC countries. Our research capabilities span across numerous industries which include, but are not limited to, chemicals, energy, mining, advanced materials, pharmaceuticals, food and beverage, and biotechnology.results.

  3. Report Description and Highlights Report Description GCC Biosimilar Market Share 2022: Industry Analysis, Price Trends, Size, Growth And Forecast Till 2027 GCC Biosimilar Market: Market Size, Share, Trends, Industry Analysis, Application Analysis, Growth and Forecast, 2022-2027” provides a deep and thorough evaluation of the GCC biosimilar market based on its segments including type, end-use, and region. The report tracks the latest industry trends and analyses their overall impact on the market. It also evaluates the market dynamics, which cover the key demand and price indicators, and studies the market on the basis of the SWOT and Porter’s Five Forces models. Report Metrics Historical Year: 2016-2021 Base Year: 2021 Forecast Year: 2022-2027 Biosimilars, also called follow-on biologics or subsequent entry biologics (SEBs), represent biotherapeutic products that are similar to reference biologic drugs. They are produced by utilizing living organisms, including plant cells and have a complex molecular structure. In line with this, to be labeled as a biosimilar, a biological drug should be similar in terms of dosage, performance, quality, strength, efficacy, safety, etc. Biosimilars manufacturers wait till the patent on the original drugs is expired and then seek approval from the regulatory authorities in order to produce their biosimilar versions. They use state-of-the-art technology to compare various characteristics, such as purity, chemical identity, bioactivity, etc., of the proposed biosimilar to its reference product.

  4. Report Description and Highlights Report Description GCC Biosimilar Market Industry Trends and Drivers: The expanding geriatric population and the growing prevalence of chronic diseases, such as cancer, diabetes, rheumatoid arthritis, etc., are primarily driving the GCC biosimilar market. Additionally, several branded biologics are nearing their expiration dates, which in turn, is catalyzing the market growth. Besides this, the launch of numerous favorable policies by government bodies and third-party payers to promote the adoption of biosimilars over branded biologics and develop strategic models for discount pricing is acting as another significant growth-inducing factor. Moreover, the elevating R&D activities in biotechnology and the increasing awareness among patients towards the availability of high-quality biosimilars that offer improved access to treatment are also positively influencing the regional market. Apart from this, the rising investments to upgrade the existing healthcare infrastructures are projected to fuel the GCC biosimilar market in the coming years. Note: Our analysts are continuously monitoring the influence of the COVID-19 pandemic on the market. This insightful information is included in the report to improve the efficiency, resilience and overall performance of businesses. Download a free sample report to get detailed insight about the market: https://www.syndicatedanalytics.com/request?type=report&id=804&flag=B

  5. Report Description and Highlights Report Description GCC Biosimilar Market Segmentation: The market is segmented on the basis of type, end-use, and region. • • • Type End use Region • • • • • North America Europe Asia Pacific Latin America Middle East and Africa Competitive Landscape: The report also provides insights on the competitive landscape of the biosimilar market with the leading players profiled in the report. Browse complete report with tables of contents and list of figures & tables:https://www.syndicatedanalytics.com/gcc- biosimilar-market

  6. Table of Contents Report Description 1 Introduction 1.1 Research Objectives 1.2 Stakeholders 1.3 Scope of the Report 1.4 Assumptions and Limitations 2 Research Methodology 2.1 Data Collection 2.1.1 Primary Sources 2.1.2 Secondary Sources 2.2 Market Size Estimation 2.2.1 Bottom-Up Approach 2.2.2 Top-Down Approach 2.3 Data Validation 3 Executive Summary 4 Introduction to Global Biosimilar Market 4.1 Overview 4.2 WHO and FDA Terminology on Biosimilars 4.3 Biosimilars and Generics 4.3 Biosimilars and Branded Biological Products 5 Biosimilar Research, Development and Manufacturing 5.1 Research and Development: Biosimilars vs. Innovator Drugs 5.2 Manufacturing: Biosimilars vs. Innovator Drugs

  7. Table of Contents Report Description 6 Global Biosimilar Market 6.1 Historical Market Trends 6.2 Market Segmentation by Region 6.3 Market Outlook 7 GCC Biosimilar Market 7.1 Industry Overview 7.2 Key Industry Developments 7.3 Market Trends 7.3.1 Key Market Indicators 7.3.2 Historical Market Trends 7.3.3 Impact of COVID-19 8 GCC Biosimilar Market Segmentation by Country 8.1 Saudi Arabia 8.1.1 Historical Market Trends 8.1.2 Market Outlook 8.2 United Arab Emirates 8.2.1 Historical Market Trends 8.2.2 Market Outlook 8.3 Qatar 8.3.1 Historical Market Trends 8.3.2 Market Outlook 8.4 Kuwait 8.4.1 Historical Market Trends 8.4.2 Market Outlook

  8. Report DescriptionTable of Contents 8.5 Oman 8.5.1 Historical Market Trends 8.5.2 Market Outlook 8.6 Bahrain 8.6.1 Historical Market Trends 8.6.2 Market Outlook 9 GCC Biosimilar Market Segmentation by Module 9.1 Infliximab 9.1.1 Historical Market Trends 9.1.2 Market Outlook 9.2 Insulin Glargine 9.2.1 Historical Market Trends 9.2.2 Market Outlook 9.3 Epoetin Alfa 9.3.1 Historical Market Trends 9.3.2 Market Outlook 9.4 Etanercept 9.4.1 Historical Market Trends 9.4.2 Market Outlook 9.5 Filgrastim 9.5.1 Historical Market Trends 9.5.2 Market Outlook 9.6 Somatropin 9.6.1 Historical Market Trends

  9. Table of Contents Report DescriptionTable of Contents 9.6.2 Market Outlook 9.7 Rituximab 9.7.1 Historical Market Trends 9.7.2 Market Outlook 9.8 Follitropin Alfa 9.8.1 Historical Market Trends 9.8.2 Market Outlook 10 GCC Biosimilar Market Segmentation by Type of Manufacturing 10.1 In-House Manufacturing 10.1.1 Historical Market Trends 10.1.2 Market Outlook 10.2 Contract Manufacturing 10.2.1 Historical Market Trends 10.2.2 Market Outlook 11 GCC Biosimilar Market Segmentation by Indication 11.1 Auto-Immune Diseases 11.1.1 Historical Market Trends 11.1.2 Market Outlook 11.2 Blood Disorder 11.2.1 Historical Market Trends 11.2.2 Market Outlook 11.3 Diabetes 11.3.1 Historical Market Trends 11.3.2 Market Outlook

  10. Table of Contents 11.4 Oncology 11.4.1 Historical Market Trends 11.4.2 Market Outlook 11.5 Growth Deficiency 11.5.1 Historical Market Trends 11.5.2 Market Outlook 11.6 Female Infertility 11.6.1 Historical Market Trends 11.6.2 Market Outlook 12 GCC Biosimilar Industry: Market Dynamics 12.1 Overview 12.2 Strengths 12.3 Weaknesses 12.4 Opportunities 12.5 Threats 13 GCC Biosimilar Industry: Value Chain Analysis 13.1 Overview 13.2 Research and Development 13.3 Raw Material Suppliers 13.4 Inbound Logistics 13.5 Production 13.6 Marketing 13.7 Outbound Logistics 13.8 Consumers

  11. Table of Contents 14 GCC Biosimilar Industry: Porter’s Five Forces Analysis 14.1 Overview 14.2 Threat of New Entrants 14.3 Threat of Substitutes 14.4 Bargaining Power of Buyers 14.5 Bargaining Power of Suppliers 14.6 Intensity of Rivalry 15 Competitive Landscape 15.1 Market Structure 15.2 Key Players 15.3 Key Success Factors 16 Key Player Profiles

  12. List of Figures Report Description Figure 1: Global: Biosimilar Market: Sales Value (in Million US$), 2016-2021 Figure 2: Global: Biosimilar Market: Segmentation by Region (in %), 2021 Figure 3: Global: Biosimilar Market Outlook: Sales Value (in Million US$), 2022-2027 Figure 4: GCC: Biosimilar Market: Sales Value (in Million US$), 2016-2021 Figure 5: GCC: Biosimilar Market Outlook: Sales Value (in Million US$), 2022-2027 Figure 6: GCC: Biosimilar Market: Segmentation by Country (in %), 2021 Figure 7: GCC: Biosimilar Market: Segmentation by Molecule (in %), 2021 Figure 8: GCC: Biosimilar Market: Segmentation by Type of Manufacturing (in %), 2021 Figure 9: GCC: Biosimilar Market: Segmentation by Indication (in %), 2021 Figure 10: Saudi Arabia: Biosimilar Market: Sales Value (in Million US$), 2016 & 2021 Figure 11: Saudi Arabia: Biosimilar Market Outlook: Sales Value (in Million US$), 2022-2027 Figure 12: United Arab Emirates: Biosimilar Market: Sales Value (in Million US$), 2016 & 2021 Figure 13: United Arab Emirates: Biosimilar Market Outlook: Sales Value (in Million US$), 2022-2027 Figure 14: Qatar: Biosimilar Market: Sales Value (in Million US$), 2016 & 2021 Figure 15: Qatar: Biosimilar Market Outlook: Sales Value (in Million US$), 2022-2027 Figure 16: Kuwait: Biosimilar Market: Sales Value (in Million US$), 2016 & 2021 Figure 17: Kuwait: Biosimilar Market Outlook: Sales Value (in Million US$), 2022-2027 Figure 18: Oman: Biosimilar Market: Sales Value (in Million US$), 2016 & 2021 Figure 19: Oman: Biosimilar Market Outlook: Sales Value (in Million US$), 2022-2027 Figure 20: Bahrain: Biosimilar Market: Sales Value (in Million US$), 2016 & 2021 Figure 21: Bahrain: Biosimilar Market Outlook: Sales Value (in Million US$), 2022-2027 Figure 22: GCC: Biosimilar (Infliximab) Market: Sales Value (in Million US$), 2016 & 2021 Figure 23: GCC: Biosimilar (Infliximab) Market Outlook: Sales Value (in Million US$), 2022-2027

  13. List of Figures Report DescriptionList of Figures Figure 24: GCC: Biosimilar (Insulin Glargine) Market: Sales Value (in Million US$), 2016 & 2021 Figure 25: GCC: Biosimilar (Insulin Glargine) Market Outlook: Sales Value (in Million US$), 2022-2027 Figure 26: GCC: Biosimilar (Epoetin Alfa) Market: Sales Value (in Million US$), 2016 & 2021 Figure 27: GCC: Biosimilar (Epoetin Alfa) Market Outlook: Sales Value (in Million US$), 2022-2027 Figure 28: GCC: Biosimilar (Etanercept) Market: Sales Value (in Million US$), 2016 & 2021 Figure 29: GCC: Biosimilar (Etanercept) Market Outlook: Sales Value (in Million US$), 2022-2027 Figure 30: GCC: Biosimilar (Filgrastim) Market: Sales Value (in Million US$), 2016 & 2021 Figure 31: GCC: Biosimilar (Filgrastim) Market Outlook: Sales Value (in Million US$), 2022-2027 Figure 32: GCC: Biosimilar (Somatropin) Market: Sales Value (in Million US$), 2016 & 2021 Figure 33: GCC: Biosimilar (Somatropin) Market Outlook: Sales Value (in Million US$), 2022-2027 Figure 34: GCC: Biosimilar (Rituximab) Market: Sales Value (in Million US$), 2016 & 2021 Figure 35: GCC: Biosimilar (Rituximab) Market Outlook: Sales Value (in Million US$), 2022-2027 Figure 36: GCC: Biosimilar (Follitropin Alfa) Market: Sales Value (in Million US$), 2016 & 2021 Figure 37: GCC: Biosimilar (Follitropin Alfa) Market Outlook: Sales Value (in Million US$), 2022-2027 Figure 38: GCC: Biosimilar (In-house Manufacturing) Market: Sales Value (in Million US$), 2016 & 2021 Figure 39: GCC: Biosimilar (In-house Manufacturing) Market Outlook: Sales Value (in Million US$),2022-2027 Figure 40: GCC: Biosimilar (Contract Manufacturing) Market: Sales Value (in Million US$), 2016 & 2021 Figure 41: GCC: Biosimilar (Contract Manufacturing) Market Outlook: Sales Value (in Million US$), 2022-2027 Figure 42: GCC: Biosimilar (Auto-Immune Diseases) Market: Sales Value (in Million US$), 2016 & 2021 Figure 43: GCC: Biosimilar (Auto-Immune Diseases) Market Outlook: Sales Value (in Million US$), 2022-2027 Figure 44: GCC: Biosimilar (Blood Disorder) Market: Sales Value (in Million US$), 2016 & 2021 Figure 45: GCC: Biosimilar (Blood Disorder) Market Outlook: Sales Value (in Million US$), 2022-2027 Figure 46: GCC: Biosimilar (Diabetes) Market: Sales Value (in Million US$), 2016 & 2021

  14. List of Figures Figure 47: GCC: Biosimilar (Diabetes) Market Outlook: Sales Value (in Million US$), 2022-2027 Figure 48: GCC: Biosimilar (Oncology) Market: Sales Value (in Million US$), 2016 & 2021 Figure 49: GCC: Biosimilar (Oncology) Market Outlook: Sales Value (in Million US$), 2022-2027 Figure 50: GCC: Biosimilar (Growth Deficiency) Market: Sales Value (in Million US$), 2016 & 2021 Figure 51: GCC: Biosimilar (Growth Deficiency) Market Outlook: Sales Value (in Million US$), 2022-2027 Figure 52: GCC: Biosimilar (Female Infertility) Market: Sales Value (in Million US$), 2016 & 2021 Figure 53: GCC: Biosimilar (Female Infertility) Market Outlook: Sales Value (in Million US$), 2022-2027 Figure 54: GCC: Biosimilar Industry: Market Dynamics Figure 55: GCC: Biosimilar Industry: Value Chain Analysis Figure 56: GCC: Biosimilar Market: Porter’s Five Forces Analysis

  15. List of Tables Report Description Table 1: GCC: Biosimilar Market: Key Industry Highlights, 2021 and 2027 Table 2: GCC: Biosimilar Market Outlook: Segmentation by Country (in Million US$), 2022-2027 Table 3: GCC: Biosimilar Market Outlook: Segmentation by Molecule (in Million US$), 2022-2027 Table 4: GCC: Biosimilar Market Outlook: Segmentation by Type of Manufacturing (in Million US$), 2022-2027 Table 5: GCC: Biosimilar Market Outlook: Segmentation by Indication (in Million US$), 2022-2027 Table 6: GCC: Biosimilar Market Structure Table 7: GCC: Biosimilar Market: Key Players

  16. Terms and Conditions Report Description © 2021 Syndicated Analytics All Rights Reserved The information and content provided on the site, such as texts, graphics, images, designs, etc. (the Content) are the copyrighted property of Syndicated Analytics or its respective licensor and are protected by the Regional and International Copyright Laws. You have a non-transferable and non- exclusive right to display, print or download the Content for your individual use on a single computer. You agree that you will not use, modify, republish or distribute the Content in any manner for commercial or other purposes. You further agree to retain all copyright or other notices on the Content. All rights not specifically granted are reserved. Disclaimer: The information and services provided by us are based on the data gathered from varied sources such as interviews, paid databases, annual reports, press releases and surveys. This data, collected in good faith, is used on an as is and as available basis and is subject to fluctuations. We do not make any guarantees and warrantees regarding the completeness, accuracy, usefulness and reliability of the data. Our information products and services are meant to be used as general information only. We insist that any business or investment decisions should not be made based solely on the information provided by us. We will not be accountable for any losses suffered by you in case of any direct, indirect, consequential or incidental damage.

  17. Contact Us FOR MORE DETAILS Visit us at : https://www.syndicatedanalytics.com Stay With Us: TELEPHONE: +1-213-316-7435 E-MAIL: sales@syndicatedanalytics.com

More Related